Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs

@article{Schnthal2008CelecoxibAT,
  title={Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs},
  author={A. Sch{\"o}nthal and Thomas C Chen and F. Hofman and S. Louie and N. Petasis},
  journal={Expert Opinion on Investigational Drugs},
  year={2008},
  volume={17},
  pages={197 - 208}
}
Celecoxib is an NSAID that was developed as a selective inhibitor of COX-2 and approved by the FDA for the treatment of various forms of arthritis and the management of acute or chronic pain. In addition, it was more recently approved as an oral adjunct to prevent colon cancer development in patients with familial adenomatous polyposis and is presently being investigated for its chemotherapeutic potential in the therapy of advanced cancers. However, in laboratory studies it was discovered that… Expand
COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro
TLDR
The antitumor activity of celecoxib in vitro did not involve the inhibition of COX-2, and the drug's ability to trigger ERS, a known effector of cell death, might provide an alternative explanation for its acute cytotoxicity. Expand
Cyclooxygenase inhibitors: Scope of their use and development in cancer chemotherapy
TLDR
The purpose of this review is to focus on the medicinal chemistry aspects of COX‐2 inhibitors in cancer chemotherapy and recent reports on these inhibitors as anticancer agents. Expand
Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells.
TLDR
Results indicate that Celecoxib is not a suitable chemosensitizer for breast cancer or with doxorubicin for other cancers, and combination of celecoxib with other drugs should be tailored to the tumor type, drug and administration schedule. Expand
Targeting apoptosis pathways by Celecoxib in cancer.
TLDR
The use of Celecoxib may be of specific value for the treatment of apoptosis-resistant tumors with overexpression of Bcl-2, Mcl-1, or survivin as single drug or in combination with radiotherapy, chemotherapy, or targeted pro-apoptotic drugs that are inhibited by survivin, BCl-2 or MCl-1. Expand
Usefulness of selective COX-2 inhibitors as therapeutic agents against canine mammary tumors.
TLDR
The results revealed that celecoxib induced apoptosis and cell cycle arrest in CF33 cells, and provided the first indication that COX-2 inhibition can provide a new therapeutic strategy for treating canine mammary tumors. Expand
Antiangiogenic Activities of 2,5-Dimethyl-Celecoxib on the Tumor Vasculature
TLDR
In vitro and in vivo analyses confirmed that 2,5-dimethyl-celecoxib has antivascular activity, and considering that DMC targets both tumor cells and tumor-associated ECs, this agent is a promising anticancer drug. Expand
Aspirin potentiates celecoxib-induced growth inhibition and apoptosis in human non-small cell lung cancer by targeting GRP78 activity
TLDR
The data suggest that cancer sensitivity to combined therapy using low concentrations of celecoxib and aspirin was higher than that of cele Coxib or aspirin alone, and combination therapy also exhibited a better inhibitory effect on tumor growth in vivo. Expand
Combination Effects of Salvianolic Acid B with Low-Dose Celecoxib on Inhibition of Head and Neck Squamous Cell Carcinoma Growth In vitro and In vivo
TLDR
It is found that salvianolic acid B (Sal-B), isolated from Salvia miltiorrhiza Bge, can effectively suppress COX-2 expression and induce apoptosis in a variety of cancer cell lines and results in a more pronounced anticancer effect in HNSCC than either agent alone. Expand
Exploiting Celecoxib in Cancer Therapy
TLDR
Preclinical investigations demonstrate promising anti-tumour activity of Celecoxib in a variety of human tumours, and Epidemiological studies suggest a lower incidence of colonic polyps in patients with the hereditary familiary adenomatous polyposis (FAP) syndrome and a decreased risk for colorectal, skin and other cancers upon continuous uptake of Cele Coxib or related compounds. Expand
COX-2 inhibitors block chemotherapeutic agent-induced apoptosis prior to commitment in hematopoietic cancer cells.
TLDR
A differential off-target anti-apoptotic effect of COX-2 inhibitors on intrinsic vs. extrinsic apoptosis at the very early steps of intracellular signaling, prior to commitment is shown, implying that an exacerbation of the chemoresistance phenomena may be implicated. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 104 REFERENCES
Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy.
TLDR
2,5-dimethyl-celecoxib (DMC), which retains the antiproliferative and apoptosis-inducing function, but completely lacks the COX-2 inhibitory activity, is able to mimic faithfully all of the numerous antitumor effects of celecoxib that have been investigated so far. Expand
Dimethyl-Celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-Inhibitory function, potently mimics the anti-tumor effects of celecoxib on burkitt’s lymphoma in vitro and in vivo
TLDR
DMC potently mimics all of the anti-proliferative and anti-tumorigenic effects of celecoxib, and effectively inhibits cell proliferation through the down-regulation of cyclins A and B and the ensuing loss of cyclin-dependent kinase activity. Expand
Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models.
TLDR
The cytotoxic effect of a specific COX-2 inhibitor, celecoxib, against LLC, HCA-7, and HCT-15 cells grown in cell culture is studied and its effect on H CA-7 cells grown as xenografts in nude mice is compared. Expand
Dimethyl celecoxib as a novel non-cyclooxygenase 2 therapy in the treatment of non-small cell lung cancer.
TLDR
2,5-dimethyl celecoxib is a structural analog of Celecoxib that lacks cyclooxygenase 2 inhibitory activity but exhibits significant antineoplastic properties comparable to celecoxIB, suggesting that the antineoproteinase activities of cele Coxib are, at least in part, cyclo Oxygenase independent and that therapeutic strategies can be developed without the side effects of global cyclo oxygengenase2 blockade. Expand
Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib.
TLDR
It is demonstrated that inhibition of proliferation and induction of apoptosis by DMC (and celecoxib) can be accomplished even in highly drug-resistant multiple myeloma cells, and that this effect is achieved via the blockage of multiple targets that are critical for multipleMyeloma cell growth and survival. Expand
Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues.
TLDR
Generic approaches to improve the balance between benefits and risks associated with the use of NSAIDs in chemoprevention are considered and strategies to overcome the various logistic and scientific barriers that impede clinical trials ofNSAIDs for cancer prevention are identified. Expand
Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention.
TLDR
Several pathways of the eicosanoid cascade that are relevant to cancer are reviewed; the evidence regarding the role of COX-2 as a target for cancer prevention is summarized; and several of the molecular targets that may mediate the chemopreventive effect of NSAIDs are discussed. Expand
Cancer Prevention: A New Era beyond Cyclooxygenase-2
TLDR
There is evidence to suggest that COX-2 may not be the only or ideal eicosanoid pathway target for cancer prevention, and that targets other than COx-2 should be pursued as alternative or complementary approaches to cancer prevention. Expand
The cyclooxygenase-2 pathway as a target for treatment or prevention of cancer
TLDR
This review focuses on the physiological function of COX, and the clinical rationale for evaluating COX-2 selective inhibitors for use in oncology. Expand
Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo
TLDR
Evidence is presented that celecoxib and DMC are able to down-regulate the expression of survivin, an anti-apoptotic protein that is highly expressed in tumor cells and known to confer resistance of such cells to anti-cancer treatments, and that these effects are not restricted to in vitro conditions, but also take place in tumors from drug-treated animals. Expand
...
1
2
3
4
5
...